Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00661 ...
Drug Name Verapamil
Molecular Weight 454.6016
Molecular Formula C27H38N2O4
CAS Number 52-53-9
SMILES COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
External Links
DRUGBANK DB00661
T3DB T3D3544
PubChem Compound 2520
PDR 1046
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Not Available

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Absorption 90.0 % >90 % PO, oral; DRUGBANK
AUC 1037.0 ng.h/ml 1037.0 ng.h/ml PO, oral; Optical rotation R; DRUGBANK
AUC 195.0 ng.h/ml 195.0 ng.h/ml PO, oral; Optical rotation S; DRUGBANK
Bioavailability 25.0 % 20-30 % PO, oral; DRUGBANK
Bioavailability 22.0 % 22±8 % PO, oral; The Pharmacological Basis of Therapeutics
Bioavailability 35.0 % 35±13 % sublingual; The Pharmacological Basis of Therapeutics
C Max 262.5 ng/ml 125-400 ng/ml PO, oral; immediate release formulation; DRUGBANK
C Max 77.8 ng/ml 77.8 ng/ml PO, oral; Optical rotation R; DRUGBANK
C Max 16.8 ng/ml 16.8 ng/ml PO, oral; Optical rotation S; DRUGBANK
C Max 272.0 ng/ml 272.0 ng/ml Tablet, PO, oral; immediate release formulation; adults; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 141.5 ng/ml 118-165 ng/ml Tablet, PO, oral; extended release formulation; adults; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 1.5 h 1-2 h PO, oral; immediate release formulation; DRUGBANK
T Max 8.5 h 6-11 h PO, oral; extended release formulation; DRUGBANK
T Max 1.1 h 1.1 h Tablet, PO, oral; immediate release formulation; adults; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 6.7 h 5.6-7.7 h Tablet, PO, oral; extended release formulation; adults; normal,healthy; The Pharmacological Basis of Therapeutics
Metabolic 80.0 % 80 % Liver metabolism; DRUGBANK
Clearance 20.4 L/h ~340 ml/min Total clearance; Oral multiple dose; DRUGBANK
Clearance 39.8 L/h ~664 ml/min Total clearance; Oral multiple dose; DRUGBANK
Clearance 60.4 L/h ~1007 ml/min Total clearance; Oral single dose; DRUGBANK
Clearance 328.9 L/h ~5481 ml/min Total clearance; Oral single dose; DRUGBANK
Clearance 39.1 L/h ~651 ml/min Total clearance; Oral multiple dose; DRUGBANK
Clearance 171.3 L/h ~2855 ml/min Total clearance; Oral multiple dose; DRUGBANK
Clearance 0.90 L/h/kg 15±6 ml/min/kg hydrolysis; hydrolysis; Children → ;Elderly ↑ ;Hepatic cirrhosis, cirr ↑ ;Obesity ↑ ;RD, renal impairment, Renal disease，including uremia → ;Attenuated Total Reflectance ↑ ;Attenuated Total Reflectance → ; The Pharmacological Basis of Therapeutics
Clearance 1.1 L/h/kg 18 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 300.0 L ~300 L DRUGBANK
Volume of Distribution 500.0 L 500.0 L DRUGBANK
Volume of Distribution 5.0 L/kg 5.0±2.1 L/kg Elderly → ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia → ;Obesity → ; The Pharmacological Basis of Therapeutics
Volume of Distribution 3.7 L/kg 3.7 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 5.1 h 2.8-7.4 h elimination half-life; immediate release formulation; Single dose; DRUGBANK
Half-life 8.3 h 4.5-12.0 h Multiple dose; DRUGBANK
Half-life 15.0 h 14-16 h elimination half-life; hepatic insufficiency; DRUGBANK
Half-life 20.0 h ~20 h Elderly; DRUGBANK
Half-life 0.0667 h ~4 min rapid distribution half-life; intravenous injection, IV; DRUGBANK
Half-life 3.5 h 2-5 h elimination half-life; DRUGBANK
Half-life 4.0 h 4.0±1.5 h Children → ;Hepatic cirrhosis, cirr ↑ ;Obesity ↑ ;atrial fibrillation ↑ ;RD, renal impairment, Renal disease，including uremia → ;Age ↑ ; The Pharmacological Basis of Therapeutics
Half-life 2.8 h 2.8 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 150.0 mg/kg 150.0 mg/kg PO, oral; Rattus, Rat; DRUGBANK
Toxicity LD50 163.0 mg/kg 163.0 mg/kg PO, oral; mouse; DRUGBANK
Toxicity LD50 8.0 mg/kg 8.0 mg/kg intravenous injection, IV; mouse; T3DB
Toxicity TDLo 14.4 mg/kg 14.4 mg/kg PO, oral;  Female, women; DRUGBANK
Toxicity TDLo 3.4 mg/kg 3.429 mg/kg PO, oral; Male, men; DRUGBANK
Eliminate Route 3.5 % ~3-4 % Urinary excretion; Unchanged drug; DRUGBANK
Eliminate Route 3.0 % <3 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 94.0 % 94 % Optical rotation R; DRUGBANK
Protein Binding 88.0 % 88 % Optical rotation S; DRUGBANK
Protein Binding 92.0 % 92 % Optical rotation R; DRUGBANK
Protein Binding 86.0 % 86 % Optical rotation S; DRUGBANK
Protein Binding 90.0 % 90±2 % Elderly → ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia → ;atrial fibrillation → ; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 8.0 mg/kg/day 8 mg/kg/day PO, oral Calan SR verapamil hydrochloride PDR
Max dose for adolescents 8.0 mg/kg/day 8 mg/kg/day PO, oral Calan SR verapamil hydrochloride PDR
Max dose for adults 480.0 mg/day 480 mg/day PO, oral Calan SR verapamil hydrochloride PDR
Max dose for adults 400.0 mg/day 400 mg/day PO, oral Calan SR verapamil hydrochloride PDR
Max dose for adults 540.0 mg/day 540 mg/day PO, oral Calan SR verapamil hydrochloride PDR
Max dose for elderly 480.0 mg/day 480 mg/day PO, oral Calan SR verapamil hydrochloride PDR
Max dose for elderly 400.0 mg/day 400 mg/day PO, oral Calan SR verapamil hydrochloride PDR
Max dose for elderly 540.0 mg/day 540 mg/day PO, oral Calan SR verapamil hydrochloride PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1